Amgen Inc.

Boehringer Ingelheim International Gmbh

Bristol-myers Squibb Compnay

Active Biotech Ab

Laboratoires Serono S.a.

Elixir Pharmaceuticals, Inc.

Thomas Stephen Coulter

Michael G Kelly

Chiara Ghiron

Ning Xi

Shimin Xu

Philip Miller

Steven Taylor

Stephen Murfin

Tanja Reuter

John F Kincaid

Christopher Harold Fotsch

Paul E Harrington

Stefan Jaekel

Babette Aicher

David J Semin

Nicholas A Meanwell

John F Kadow

Jeffrey O Saunders

Andrew Stewart Tasker

Anna Quattropani

Kap-Sun Yeung

Matthias Schwarz

Manuel A Navia

Russell Thomas

Gilbert M Rishton

David Joseph St Jean, Jr

Ian Richard Matthews

Steve Fong Poon

J J Kim Wright

Jean-Francois Pons

Muhammed Kamal Uddin

Malcolm Taylor

Philip Huxley

Stefan Jäkel

Chris James Brennan

Lars Olof Göran Pettersson

Dorthe Da Graca Thrige

Jj Kim Wright

David Johnston

Paul Mortenson

Michelle E Farkas

Robert Townsend

Valery Thammalaksa

Qing Ping Zeng

Adam James Davenport

Arndt-René Kelter

Michelle Farkas

The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. 

Pyrrolopyrimidines for pharmaceutical compositions

The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes. 

Calcium receptor modulating agents

The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I. 

The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2or Mnk2) and/or variants thereof.

Mnk1 or Mnk2 inhibitors

This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein:   

Indole, azaindole and related heterocyclic N-substituted piperazine derivatives

Compounds that modulate GHS-R are described, for examples compounds formula (I) 

Sulfonamide compounds and uses thereof

The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

Triazoles as oxytocin antagonists

The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

Immunomodulatory compounds

The compounds of the invention are represented by the following general structureor a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Growing community of inventors

Wantage, United Kingdom

Thomas Stephen Coulter